Seeking Alpha

The heavy promotion of Galena Biopharma (GALE +3.3%) across the Internet doesn't quite make...

The heavy promotion of Galena Biopharma (GALE +3.3%) across the Internet doesn't quite make sense if the chatter is true that the company is lined up as an acquisition target by Big Pharma, according to Michael Morhamus. Unfazed by the stock's 510% YTD return on the promise of its breast cancer treatment, he notes that institutional money avoids "highly promoted" stocks like GALE.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector